6 days ago · Daily news and analysis of the global biotechnology and pharmaceutical industries. In-depth coverage of business, financing, regulation, science, innovation, drug approvals, clinical trials and more.

Oct 31, 2024 · Researchers from Mariana Oncology Inc. reported preclinical data on MC-339, a DLL3-targeting macrocyclic peptide in several tumor models. Delta-like ligand 3 (DLL3) is overexpressed on the cell surface of small-cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC) and metastatic melanoma.

Feb 21, 2025 · A new version of Evo, the AI developed at the Arc Institute that can be used to design genomes as long as that of a bacterium, has been retrained with the DNA sequences of three domains of life – viruses, bacteria and eukaryotes.

Mar 25, 2025 · In a move that echoes tariff threats from U.S. President Donald Trump, the Pharmaceutical Research and Manufacturers of America (PhRMA) lobby is taking aim at most of the world for unfair trade practices in its special 2025 Special 301 Report to …

Feb 14, 2025 · Biopharma deal activity in the first month of the year saw the largest January raise thus far, with $28.63 billion in collective funds. While down slightly month over month, the value was comparable to December 2024’s $29.02 billion and November 2024’s $29.34 billion.

Dec 27, 2024 · A preview of the next edition of BioWorld, Dec. 27, 2024. Kaken Pharmaceutical Co. Ltd. signed a license agreement with Johnson & Johnson (J&J) for the global development, manufacturing and sale of KP-723, a signal transducer and activator of transcription (STAT)6 inhibitor at the preclinical stage.

Mar 5, 2025 · Kyorin Pharmaceutical Co. Ltd. has out-licensed its preclinical candidate, KRP-M223, and its back-up compounds to Novartis Pharma AG in a deal worth up to $777.5 million. Under the terms, Novartis gains an exclusive worldwide license to develop, manufacture and commercialize Kyorin-discovered KRP-M223.

Jan 10, 2025 · Biopharma stocks saw a year of ups and downs in 2024, with the BioWorld Stock Index rising as much as 21% before dipping below 2% and ultimately closing the year up 5.16%. This performance follows a 33.59% gain in 2023 and a sharp 32.75% decline in 2022. Among the 509 stocks analyzed in the index, 169 companies (33%) ended the year with gains, while 340 (67%) saw their shares decline.

These cookies are used to enable social media sharing or “like” buttons on our services. They also provide the ability to link your account or engage with our content on or through a social media platform such as Facebook, Twitter or LinkedIn.

Jan 3, 2025 · These graphs compare the performance of the biotech stocks for all of 2024 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.